Search Results

You are looking at 31 - 40 of 80 items for :

  • "Dabrafenib" x
  • Refine by Access: All x
Clear All
Full access

David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

on data showing the efficacy of dabrafenib/trametinib (see NSCL-17, page 809). 65 , 68 Real-time PCR, Sanger sequencing, and NGS are the most commonly used methods to assess for BRAF mutations (see NSCL-G, pages 815–818). Dabrafenib and trametinib

Full access

Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah

Background : Both immunotherapy (IO) and targeted therapy, specifically dabrafenib + trametinib (DT), are recommended by the NCCN guidelines for the management of BRAF+ cutaneous melanoma in the adjuvant setting. However, data surrounding their

Full access

Presenters: Douglas B. Johnson, Susan M. Swetter, April K.S. Salama, and Evan Wuthrick

combination of dabrafenib + trametinib has been shown to improve clinical outcomes in BRAF V600–mutant metastatic melanoma without brain metastases. In the phase II COMBI-MB trial, however, investigators explored the activity of dabrafenib + trametinib in

Full access

Presenter: Lori J. Wirth

fusions. 9 Gene-Specific Therapy in Thyroid Cancer In a phase II study of patients with iodine-refractory PTC and BRAF V600E mutations, BRAF ‐directed therapy with dabrafenib ± trametinib was well-tolerated and did display efficacy, but

Full access

Karolina Kata, Juan C. Rodriguez-Quintero, Octavio D. Arevalo, Jackie J. Zhang, Meenakshi Bidwai Bhattacharjee, Cornelius Ware, Antonio Dono, Roy Riascos-Castaneda, Nitin Tandon, Angel Blanco, Yoshua Esquenazi, Leomar Y. Ballester, Mark Amsbaugh, Arthur L. Day, and Jay-Jiguang Zhu

mass in April 2018 ( Figure 2D–F ). Subsequent MRI confirmed tumor progression, and in September 2018 his chemotherapy was changed to the second-generation BRAF inhibitor dabrafenib + lomustine. He was stable for 9 months. In January 2019, he received

Full access

Leora Horn

adenocarcinoma who are smokers. Dr. Horn briefly looked at early study data with both crizotinib and the BRAF V600E inhibitor dabrafenib. First, crizotinib appeared to be more effective in ROS1 -positive NSCLC than in ALK -positive NSCLC, with an objective

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

patient with BRAF -mutant cholangiocarcinoma. 50 Therefore, the panel voted to add this regimen as an additional option for patients with BRAF V600E–mutant mCRC. Next, the panel discussed whether dabrafenib could be substituted for vemurafenib by

Full access

Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Barker, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Morganna Freeman, Anjela Galan, Brian Gastman, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Sameer Nath, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeffrey Sosman, Susan M. Swetter, Kenneth K. Tanabe, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh

and safety data from prospective randomized controlled trials testing some of these immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) and targeted therapies (vemurafenib, dabrafenib/trametinib) for adjuvant treatment of high

Full access

Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J. Hicks, Grant A. McArthur, Christopher Angel, Benjamin Solomon, and Danny Rischin

the subclavian vein, off-label, compassionately accessed dabrafenib at 150 mg twice daily was commenced. At commencement of BRAF inhibitor therapy, a restaging baseline FDG-PET scan was performed ( Figure 1A ). After discharge, the patient reported

Full access

Wells A. Messersmith

guidelines now include dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor) + cetuximab or panitumumab (EGFR antibody), or encorafenib (BRAF inhibitor) + binimetinib (MEK inhibitor) + cetuximab or panitumumab ( Figure 2 ). Figure 2. Update to the NCCN